ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

Published on June 11, 2013 at 12:14 PM · No Comments

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of the Phase 2 trial of Iclusig® (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The trial is designed to provide initial clinical data evaluating the efficacy and safety of ponatinib in patients with GIST following failure of prior tyrosine kinase inhibitor (TKI) therapy.

“Patients with GIST have limited treatment options following development of resistance to TKI therapy, and we are pleased to work with leading clinical research sites to investigate ponatinib as a new treatment for these patients.”

"This trial represents an important step in ponatinib's expanded clinical development beyond Philadelphia-positive leukemias and into solid tumors. KIT is a clinically validated oncogenic target for GIST and is known to drive approximately 85 percent of these cancers. In preclinical studies ponatinib was highly potent against activated KIT and most of its resistance mutants," stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer of ARIAD. "Patients with GIST have limited treatment options following development of resistance to TKI therapy, and we are pleased to work with leading clinical research sites to investigate ponatinib as a new treatment for these patients."

Trial Design

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post